Journal
SCHIZOPHRENIA BULLETIN
Volume 39, Issue 4, Pages 807-814Publisher
OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbr195
Keywords
hallucination; schizophrenia; aetiology; neurochemistry; subclinical; PET; symptom; dopamine; psychosis continuum
Categories
Funding
- Medical Research Council UK [MC_US_A655_002_2135_0000]
- Biomedical Research Council
- Dutch Brain Foundation (Hersenstichting Nederland)
- Medical Research Council [1116129, MC_U120097115, G0700995] Funding Source: researchfish
- MRC [G0700995, MC_U120097115] Funding Source: UKRI
Ask authors/readers for more resources
Background: The psychosis phenotype appears to exist in the population as a continuum, but it is not clear if subclinical psychotic symptoms and psychotic disorders share the same neurobiology. We investigated whether the dopaminergic dysfunction seen in psychotic disorders is also present in healthy, well-functioning people with hallucinations. Methods: We compared dopamine synthesis capacity (using 6-[F-18]fluoro-L-DOPA [[F-18]-DOPA] positron emission tomography imaging) in 16 healthy individuals with frequent persistent auditory verbal hallucinations (hallucinating group) with that in 16 matched controls. Results: There was no significant difference in dopamine synthesis capacity in the striatum, or its functional subdivisions, between groups and no relationship between subclinical psychotic symptom severity or schizotypal traits and dopamine synthesis capacity in the hallucinating group. Conclusions: Altered dopamine synthesis capacity is unlikely to underlie subclinical hallucinations, suggesting that although there may be a phenomenological psychosis continuum, there are distinctions at the neurobiological level.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available